![Meike Heurich-Sevcenco](https://profiles-cardiff.imgix.net/attachments/2919?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Meike Heurich-Sevcenco
- Ar gael fel goruchwyliwr ôl-raddedig
Timau a rolau for Meike Heurich-Sevcenco
Uwch Ddarlithydd
Trosolwyg
Rwy'n Uwch Ddarlithydd yn yr Ysgol Fferylliaeth a Gwyddorau Fferyllol ar ôl ymuno â'r Ysgol yn 2017 (2008-2016, Ysgol Feddygaeth, Prifysgol Caerdydd) lle rwy'n arwain grŵp ymchwil sy'n canolbwyntio ar ddarganfod a nodweddu swyddogaethol croessiarad moleciwlaidd proteinau gwaed y systemau cyflenwad imiwnedd a cheulo. Rydym yn arbenigo mewn dulliau bioffisegol (Biacore) a phrofion gweithgaredd ategu a cheulo.
Rwyf hefyd yn ymchwilio i pathoffisioleg y systemau complemetn a cheulo mewn clefydau, gyda ffocws clinigol penodol ar rôl newidiadau cyflenwi a cheulo yn y gwaed mewn cleifion seicosis a sgitsoffrenia.
Rydym yn gweithio ar adnabod biofarcwyr gwaed newydd a allai ragweld datblygiad seicosis, neu ymateb triniaeth mewn sgitsoffrenia, a nodi targedau therapiwtig posibl trwy ddadansoddi cydrannau cyflenwi a cheulo a'u cynhyrchion actifadu mewn plasma gwaed mewn clefyd. Rydym yn defnyddio ELISA yn rheolaidd i feintioli proteinau mewn plasma gwaed.
Rydym wedi datblygu offer moleciwlaidd sy'n gallu modiwleiddio swyddogaeth proteinau cyflenwad a cheulo dethol ar gyfer dilysu targed a darganfod cyffuriau cynnar.
Geiriau allweddol: gwaed; system imiwnedd gynhenid, ategu; ceulo; Seicosis
Cyhoeddiad
2024
- Heurich, M., Föcking, M. and Cotter, D. 2024. Complement C4, C4A and C4a – what they do and how they differ. Brain, Behavior, & Immunity - Health 39, article number: 100809. (10.1016/j.bbih.2024.100809)
- Byrne, J. F. et al. 2024. Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies. Brain, Behavior, and Immunity 119, pp. 188-196. (10.1016/j.bbi.2024.03.049)
- Kodosaki, E. et al. 2024. Sample processing time but not storage time affects complement activation markers C4a, C4d, C3a, C3d, Bb, C5a, and sC5b-9 levels in EDTA-plasma of individuals at clinical high-risk for psychosis. Biomarkers in Neuropsychiatry 10, article number: 100097. (10.1016/j.bionps.2024.100097)
- Byrne, J. F. et al. 2024. Proteomic biomarkers for the prediction of transition to psychosis in individuals at clinical high risk: A multi-cohort model development study. Schizophrenia Bulletin 50(3), pp. 579-588. (10.1093/schbul/sbad184)
- Healy, C. et al. 2024. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms. Brain, Behavior, and Immunity 117, pp. 175-180. (10.1016/j.bbi.2023.12.018)
2023
- Heurich, M. and McCluskey, G. 2023. Complement and coagulation crosstalk - Factor H in the spotlight. Immunobiology 228(6), article number: 152707. (10.1016/j.imbio.2023.152707)
- Cropley, V., Kittel, M., Heurich-Sevcenco, M., Föcking, M., Leweke, F. and Pantelis, C. 2023. Complement proteins are elevated in blood serum but not CSF in clinical high-risk and antipsychotic-naïve first-episode psychosis. Brain, Behavior, and Immunity 113, pp. 136-144. (10.1016/j.bbi.2023.07.004)
- Susai, S. R. et al. 2023. Association of complement and coagulation pathway proteins with treatment response in first-episode psychosis: a longitudinal analysis of the OPTiMiSE clinical trial. Schizophrenia Bulletin: The Journal of Psychoses and Related Disorders 49(4), pp. 893-902. (10.1093/schbul/sbac201)
2022
- Susai, S. R. et al. 2022. Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis. Translational Psychiatry 12, article number: 454. (10.1038/s41398-022-02217-0)
- Heurich, M., Föcking, M., Mongan, D., Cagney, G. and Cotter, D. R. 2022. Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis. Molecular Psychiatry 27, pp. 127-140. (10.1038/s41380-021-01197-9)
2021
- Baker, A. T. et al. 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7(49), article number: eabl8213. (10.1126/sciadv.abl8213)
- Pathare, N., Szakmany, T., Hall, J. E. and Heurich, M. 2021. Plasma IgM levels differentiate between survivors and non-survivors of culture-positive and culture-negative sepsis and SIRS: a pilot study. Journal of Clinical Medicine 10(22), article number: 5391. (10.3390/jcm10225391)
- Howes, O., Cummings, C. and Heurich, M. 2021. Translation from genes to mechanism in schizophrenia: are immune-synaptic interactions the missing link?. Biological Psychiatry 90(9), pp. 593-595. (10.1016/j.biopsych.2021.08.014)
- Flude, B. M. et al. 2021. Targeting the complement serine protease MASP-2 as a therapeutic strategy for coronavirus infections. Viruses 13(2), article number: 312. (10.3390/v13020312)
- Mongan, D. et al. 2021. Development of proteomic prediction models for transition to psychotic disorder in the clinical high-risk state and psychotic experiences in adolescence. JAMA Psychiatry 78(1), pp. 77-90. (10.1001/jamapsychiatry.2020.2459)
2019
- Madrid-Gambin, F. et al. 2019. Integrated lipidomics and proteomics point to early blood-based changes in childhood preceding later development of psychotic experiences: evidence from the Avon Longitudinal Study of Parents and Children. Biological Psychiatry 86(1), pp. 25-34. (10.1016/j.biopsych.2019.01.018)
- Föcking, M. et al. 2019. Complement pathway changes at age 12 are associated with psychotic experiences at age 18 in a longitudinal population-based study: evidence for a role of stress. Molecular Psychiatry 26, pp. 524-533. (10.1038/s41380-018-0306-z)
2016
- Heurich-Sevcenco, M., Preston, R., O'Donnell, V. B., Morgan, B. P. and Collins, P. W. 2016. Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research 145, pp. 84-92. (10.1016/j.thromres.2016.07.017)
2015
- Martínez-Barricarte, R. et al. 2015. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Molecular Immunology 66(2), pp. 263-273. (10.1016/j.molimm.2015.03.248)
- Szakmany, T. and Heurich-Sevcenco, M. 2015. Immunomodulation in sepsis - why blunting the response doesn't work?. Journal of Infection 71(2), pp. 147-149. (10.1016/j.jinf.2015.04.019)
2014
- Ruseva, M. and Heurich-Sevcenco, M. 2014. Purification and characterization of human and mouse complement C3. In: Gadjeva, M. ed. The Complement System: Methods and Protocols., Vol. 1100. Methods in Molecular Biology Humana Press, pp. 75-91., (10.1007/978-1-62703-724-2_6)
2013
- Heurich, M., Altintas, Z. and Tothill, I. 2013. Computational Design of Peptide Ligands for Ochratoxin A. Toxins 5(6), pp. 1202-1218. (10.3390/toxins5061202)
2012
- Harris, C. L., Heurich, M., Rodriguez de Cordoba, S. and Morgan, B. P. 2012. The complotype: dictating risk for inflammation and infection. Trends in Immunology 33(10), pp. 513-521. (10.1016/j.it.2012.06.001)
2011
- Heurich, M., Martinez-Barricarte, R., Francis, N., Roberts, D. L., Rodriguez de Cordoba, S., Morgan, B. P. and Harris, C. L. 2011. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proceedings of the National Academy of Sciences of the United States of America 108(21), pp. 8761-8766. (10.1073/pnas.1019338108)
2010
- Martínez-Barricarte, R. et al. 2010. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. Journal of Clinical Investigation 120(10), pp. 3702-3712. (10.1172/JCI43343)
Adrannau llyfrau
- Ruseva, M. and Heurich-Sevcenco, M. 2014. Purification and characterization of human and mouse complement C3. In: Gadjeva, M. ed. The Complement System: Methods and Protocols., Vol. 1100. Methods in Molecular Biology Humana Press, pp. 75-91., (10.1007/978-1-62703-724-2_6)
Erthyglau
- Heurich, M., Föcking, M. and Cotter, D. 2024. Complement C4, C4A and C4a – what they do and how they differ. Brain, Behavior, & Immunity - Health 39, article number: 100809. (10.1016/j.bbih.2024.100809)
- Byrne, J. F. et al. 2024. Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies. Brain, Behavior, and Immunity 119, pp. 188-196. (10.1016/j.bbi.2024.03.049)
- Kodosaki, E. et al. 2024. Sample processing time but not storage time affects complement activation markers C4a, C4d, C3a, C3d, Bb, C5a, and sC5b-9 levels in EDTA-plasma of individuals at clinical high-risk for psychosis. Biomarkers in Neuropsychiatry 10, article number: 100097. (10.1016/j.bionps.2024.100097)
- Byrne, J. F. et al. 2024. Proteomic biomarkers for the prediction of transition to psychosis in individuals at clinical high risk: A multi-cohort model development study. Schizophrenia Bulletin 50(3), pp. 579-588. (10.1093/schbul/sbad184)
- Healy, C. et al. 2024. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms. Brain, Behavior, and Immunity 117, pp. 175-180. (10.1016/j.bbi.2023.12.018)
- Heurich, M. and McCluskey, G. 2023. Complement and coagulation crosstalk - Factor H in the spotlight. Immunobiology 228(6), article number: 152707. (10.1016/j.imbio.2023.152707)
- Cropley, V., Kittel, M., Heurich-Sevcenco, M., Föcking, M., Leweke, F. and Pantelis, C. 2023. Complement proteins are elevated in blood serum but not CSF in clinical high-risk and antipsychotic-naïve first-episode psychosis. Brain, Behavior, and Immunity 113, pp. 136-144. (10.1016/j.bbi.2023.07.004)
- Susai, S. R. et al. 2023. Association of complement and coagulation pathway proteins with treatment response in first-episode psychosis: a longitudinal analysis of the OPTiMiSE clinical trial. Schizophrenia Bulletin: The Journal of Psychoses and Related Disorders 49(4), pp. 893-902. (10.1093/schbul/sbac201)
- Susai, S. R. et al. 2022. Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis. Translational Psychiatry 12, article number: 454. (10.1038/s41398-022-02217-0)
- Heurich, M., Föcking, M., Mongan, D., Cagney, G. and Cotter, D. R. 2022. Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis. Molecular Psychiatry 27, pp. 127-140. (10.1038/s41380-021-01197-9)
- Baker, A. T. et al. 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7(49), article number: eabl8213. (10.1126/sciadv.abl8213)
- Pathare, N., Szakmany, T., Hall, J. E. and Heurich, M. 2021. Plasma IgM levels differentiate between survivors and non-survivors of culture-positive and culture-negative sepsis and SIRS: a pilot study. Journal of Clinical Medicine 10(22), article number: 5391. (10.3390/jcm10225391)
- Howes, O., Cummings, C. and Heurich, M. 2021. Translation from genes to mechanism in schizophrenia: are immune-synaptic interactions the missing link?. Biological Psychiatry 90(9), pp. 593-595. (10.1016/j.biopsych.2021.08.014)
- Flude, B. M. et al. 2021. Targeting the complement serine protease MASP-2 as a therapeutic strategy for coronavirus infections. Viruses 13(2), article number: 312. (10.3390/v13020312)
- Mongan, D. et al. 2021. Development of proteomic prediction models for transition to psychotic disorder in the clinical high-risk state and psychotic experiences in adolescence. JAMA Psychiatry 78(1), pp. 77-90. (10.1001/jamapsychiatry.2020.2459)
- Madrid-Gambin, F. et al. 2019. Integrated lipidomics and proteomics point to early blood-based changes in childhood preceding later development of psychotic experiences: evidence from the Avon Longitudinal Study of Parents and Children. Biological Psychiatry 86(1), pp. 25-34. (10.1016/j.biopsych.2019.01.018)
- Föcking, M. et al. 2019. Complement pathway changes at age 12 are associated with psychotic experiences at age 18 in a longitudinal population-based study: evidence for a role of stress. Molecular Psychiatry 26, pp. 524-533. (10.1038/s41380-018-0306-z)
- Heurich-Sevcenco, M., Preston, R., O'Donnell, V. B., Morgan, B. P. and Collins, P. W. 2016. Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research 145, pp. 84-92. (10.1016/j.thromres.2016.07.017)
- Martínez-Barricarte, R. et al. 2015. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Molecular Immunology 66(2), pp. 263-273. (10.1016/j.molimm.2015.03.248)
- Szakmany, T. and Heurich-Sevcenco, M. 2015. Immunomodulation in sepsis - why blunting the response doesn't work?. Journal of Infection 71(2), pp. 147-149. (10.1016/j.jinf.2015.04.019)
- Heurich, M., Altintas, Z. and Tothill, I. 2013. Computational Design of Peptide Ligands for Ochratoxin A. Toxins 5(6), pp. 1202-1218. (10.3390/toxins5061202)
- Harris, C. L., Heurich, M., Rodriguez de Cordoba, S. and Morgan, B. P. 2012. The complotype: dictating risk for inflammation and infection. Trends in Immunology 33(10), pp. 513-521. (10.1016/j.it.2012.06.001)
- Heurich, M., Martinez-Barricarte, R., Francis, N., Roberts, D. L., Rodriguez de Cordoba, S., Morgan, B. P. and Harris, C. L. 2011. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proceedings of the National Academy of Sciences of the United States of America 108(21), pp. 8761-8766. (10.1073/pnas.1019338108)
- Martínez-Barricarte, R. et al. 2010. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. Journal of Clinical Investigation 120(10), pp. 3702-3712. (10.1172/JCI43343)
- Heurich-Sevcenco, M., Preston, R., O'Donnell, V. B., Morgan, B. P. and Collins, P. W. 2016. Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research 145, pp. 84-92. (10.1016/j.thromres.2016.07.017)
- Martínez-Barricarte, R. et al. 2015. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Molecular Immunology 66(2), pp. 263-273. (10.1016/j.molimm.2015.03.248)
Ymchwil
Meysydd ymchwil
- Mecanweithiau cyflenwi a cheulo croessiarad moleciwlaidd mewn iechyd a chlefydau
- Rôl llwybrau cyflenwad a cheulo wedi'u newid mewn seicosis a sgitsoffrenia
- Biofarcwyr gwaed
- Ategu therapiwteg
Mae fy ymchwil yn y gorffennol wedi canolbwyntio'n bennaf ar nodweddu dadansoddiad strwythur-swyddogaeth protein sy'n arwain at gamreoleiddio y system gyflenwad, rhan o'r amddiffyniad imiwnedd cynhenid, gan gynnwys y complotype.
https://doi.org/10.1016%2Fj.molimm.2015.03.248
https://doi.org/10.1016%2Fj.it.2012.06.001
https://doi.org/10.1073%2Fpnas.1019338108
https://doi.org/10.1172%2Fjci43343
Mae fy labordy ymchwil yn yr Ysgol Fferylliaeth yn ymchwilio i'r croessiarad moleciwlaidd rhwng y ddwy system amddiffyn gynhenid yn erbyn i) goresgyniad pathogen a ii) gwaedu, sef ategu a cheulo. Mae systemau cyflenwi a cheulo yn rhaeadrau protein tebyg yn strwythurol a sefydliadol sy'n cael eu actifadu gan sbardunau diffiniedig, yn aml yn gyfochrog.
Mae camreoleiddio y systemau hyn wedi bod yn gysylltiedig â llawer o glefydau gyda patholeg pro-lidiol a pro-ceulo.
Ar hyn o bryd rydym yn astudio croessiarad cyflenwi a cheulo ar lefel protein a chellog in vitro ac yn ymchwilio i fecanweithiau in vivo.
Mae prosiectau cyfredol yn cynnwys:
i) Gyda chydweithwyr clinigol yn yr Ysgol Feddygaeth a Bwrdd Iechyd Cymru Caerdydd , rydym yn dadansoddi effaith ffactor cyflenwad H ar swyddogaeth ceulo gan adeiladu ar waith yn y gorffennol sy'n nodweddu croessiarad thrombomodulin rheoleiddiwr ceulo gyda ffactor rheoleiddiwr cyflenwad H.
https://doi.org/10.1016%2Fj.thromres.2016.07.017
Gellir ystyried ein gwaith diweddaraf sy'n disgrifio "Mae Ffactor Rheoleiddiwr Cyflenwi H yn Cofactor ar gyfer Thrombin mewn Rolau Pro- a Anticoagulant" fel rhagbrint testun llawn: https://www.biorxiv.org/content/10.1101/2021.07.22.452893v1
ii) Mewn cydweithrediad â chydweithwyr yn RCSI Dulyn , mae fy labordy yn astudio effaith actifadu cyflenwad a cheulo mewn unigolion sy'n symud ymlaen i brofiadau seicotig neu anhwylderau seicotig.
Mae ein herthygl adolygu "Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis" yn disgrifio rolau annatod y llwybrau hyn a gludir gan waed yn natblygiad seicosis. Gallwch weld yr erthygl adolygu yma: https://www.nature.com/articles/s41380-021-01197-9
Cyfleoedd PhD
(HUNAN-ARIANNU YN UNIG)
Mae Dr Heurich yn cynnig sawl cyfle i fyfyrwyr PhD i fyfyrwyr hunan-ariannu.
E-bostiwch heurichm@cardiff.ac.uk am ymholiadau pellach.
Addysgu
- Mewngofnodi
- Modiwl PH1123: Strwythur a swyddogaeth celloedd (Modiwl Arwain)
- Modiwl PH1124: Systemau'r corff dynol - Imiwnoleg Sylfaenol (Arweinydd Uned)
- Modiwl PH2113: Cyffuriau a Chlefydau 1 - Imiwnoleg Glinigol (Arweinydd Uned)
- Modiwl PH3113: Cyffuriau a Chlefydau 2 - Rhewmatoleg (Darlith)
- Modiwl PH4116: Prosiectau Ymchwil
- MSc Bioleg Canser
- PHT804 MSc Bioleg Canser - Dulliau Ymchwil (Ymarferol)
Bywgraffiad
08/2022 - presennol - Uwch Ddarlithydd
Ymchwil mewn Biocemeg Protein a Therapiwteg Arbrofol, Coleg y Gwyddorau Biofeddygol a Bywyd, Ysgol Fferylliaeth a Gwyddorau Fferyllol, Prifysgol Caerdydd, y DU.
01/2017 – Darlithydd (Addysgu ac Ymchwil)
06/2016 -12/2016 Uwch Ôl-ddoethuriaeth mewn Firoleg Moleciwlaidd, Coleg y Gwyddorau Biofeddygol a Bywyd, Ysgol Feddygaeth, Sefydliad Heintiau ac Imiwnedd, Prifysgol Caerdydd, y DU
03/2012 – 06/2016 Cymrodoriaeth Ymchwil Datblygiad Gyrfa, Coleg y Gwyddorau Biofeddygol a Bywyd, Ysgol Feddygaeth, Sefydliad Heintiau ac Imiwnedd, Prifysgol Caerdydd, DU
09/2011 – 02/2012 Cydymaith Ôl-ddoethurol/Ymchwil mewn Bioleg Ategu, Sefydliad Meddygaeth Seicolegol a Niwrowyddorau Clinigol a'r Sefydliad Heintiau ac Imiwnedd, Ysgol Feddygaeth, Prifysgol Caerdydd, y DU.
09/2008 – 08/2011 Cydymaith Ôl-ddoethurol/Ymchwil mewn Bioleg Ategu, Adran Heintiau, Imiwnedd a Biocemeg, Ysgol Feddygaeth, Prifysgol Caerdydd, DU.
04/2007-07/2008 Cynorthwyydd Ymchwil mewn Bioleg Ategu, Adran Biocemeg Feddygol, Ysgol Feddygaeth, Prifysgol Caerdydd, y DU.
Addysg
04/2004 – 04/2008 PhD mewn Ymchwil Biocemegol a Bioffisegol, Canolfan Biotechnoleg Cranfield, Prifysgol Cranfield, y DU.
10/1997 – 09/2003 Gradd Diploma mewn Biocemeg, Prifysgol Potsdam, yr Almaen
Contact Details
+44 29208 76657
Adeilad Redwood , Ystafell 2.57B, Rhodfa'r Brenin Edward VII, Caerdydd, CF10 3NB
